LC2767 Alleviates Cholestatic Liver Injury and Fibrosis in Bile Duct‐Ligated Mice
Journal of Gastroenterology and Hepatology · 25.10.2026
DOI: 10.1111/jgh.70803 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 25.10.2026. Verfasst von Dong-Yun Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lab of Microbiology and Immunology, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Commercializations Promotion Agency for R and D Outcomes.
Abstract (Originalsprache)
Background
LC2767, a mix of Lactiplantibacillus plantarum LC27 and Bifidobacterium longum LC67, protects against lipopolysaccharide (LPS)–induced liver injury. In this study, we examined whether LC2767 could alleviate cholestatic liver injury and fibrosis in bile duct‐ligated mice.
Methods
Mice with cholestatic liver injury were prepared by bile duct ligation (BDL). Biomarker levels were measured by enzyme‐linked immunosorbent assay, quantitative real‐time polymerase chain reaction, immunoblotting, or immunofluorescence staining. The gut microbiota composition was analyzed using the Illumina iSeq 100 platform.
Results
Bile duct ligation (BDL) significantly elevated alanine aminotransferase (ALT), bile acid, and lipopolysaccharide (LPS) levels, accompanied by hepatic inflammation and fibrosis, gut inflammation, and gut microbiota dysbiosis. Oral administration of LC2767 significantly attenuated BDL‐induced elevations in liver injury markers, bile acid, and LPS levels in the blood, collagen‐1, α‐smooth muscle actin, tumor necrosis factor (TNF)‐α, and cytochrome P450 family 7 subfamily A member 1 (CYP7A1) expression, NF‐κB + F4/80 + cell number, and steatosis and fibrosis scores in the liver and TNF‐α expression in the colon. In parallel, LC2767 restored BDL‐suppressed small heterodimer partner (SHP, NR0B2) and farnesoid X receptor (FXR, NR1H4) expression in the liver and colon. LC2767 partially alleviated BDL‐induced gut dysbiosis: It increased BDL‐suppressed Anaerotignaceae and Dehalobacterium _f populations and decreased BDL‐induced AC160630_f and PAC001446_f populations. LC2767 also decreased BDL‐induced LPS levels in the blood and feces.
Conclusion
LC2767 may alleviate cholestatic liver injury and fibrosis, accompanied by changes in FXR/SHP expression, NF‐κB activation, and gut microbiota composition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lab of Microbiology and Immunology, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.
- NVP Healthcare, Suwon, Republic of Korea.
- PBLbiolab, Seoul, Republic of Korea.
ORCID-Profile: Dong-Yun Lee, Seung-Won Han, Dong-Hyun Kim
Förderung
- Commercializations Promotion Agency for R and D Outcomes
Zitieren
APA
Lee, D. Y., Jang, H. M., Shin, J. W., Shin, Y. J., Kim, S. H., Han, S. W., & Kim, D. H. (2026). LC2767 Alleviates Cholestatic Liver Injury and Fibrosis in Bile Duct‐Ligated Mice. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70803
Vancouver
Lee DY, Jang HM, Shin JW, Shin YJ, Kim SH, Han SW, et al. LC2767 Alleviates Cholestatic Liver Injury and Fibrosis in Bile Duct‐Ligated Mice. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70803
BibTeX
@article{Lee2026,
author = {Lee, Dong-Yun and Jang, Hyo-Min and Shin, Jung-Woo and Shin, Yoon-Jung and Kim, Sung Hye and Han, Seung-Won and Kim, Dong-Hyun},
title = {LC2767 Alleviates Cholestatic Liver Injury and Fibrosis in Bile Duct‐Ligated Mice},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70803}
}
EUVIMED